- Home
- HOPE vs TVTX Comparison
HOPE vs TVTX Comparison
Compare HOPE & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOPE
- TVTX
- Stock Information
- Founded
- HOPE 1986
- TVTX 2008
- Country
- HOPE United States
- TVTX United States
- Employees
- HOPE N/A
- TVTX N/A
- Industry
- HOPE Major Banks
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- HOPE Finance
- TVTX Health Care
- Exchange
- HOPE Nasdaq
- TVTX Nasdaq
- Market Cap
- HOPE 1.3B
- TVTX 1.4B
- IPO Year
- HOPE 1996
- TVTX N/A
- Fundamental
- Price
- HOPE $10.16
- TVTX $14.31
- Analyst Decision
- HOPE Buy
- TVTX Strong Buy
- Analyst Count
- HOPE 3
- TVTX 15
- Target Price
- HOPE $13.50
- TVTX $33.57
- AVG Volume (30 Days)
- HOPE 741.0K
- TVTX 1.6M
- Earning Date
- HOPE 07-28-2025
- TVTX 07-31-2025
- Dividend Yield
- HOPE 5.51%
- TVTX N/A
- EPS Growth
- HOPE N/A
- TVTX N/A
- EPS
- HOPE 0.78
- TVTX N/A
- Revenue
- HOPE $448,793,000.00
- TVTX $273,533,000.00
- Revenue This Year
- HOPE $17.54
- TVTX $73.84
- Revenue Next Year
- HOPE $12.05
- TVTX $46.72
- P/E Ratio
- HOPE $13.03
- TVTX N/A
- Revenue Growth
- HOPE N/A
- TVTX 75.65
- 52 Week Low
- HOPE $8.83
- TVTX $6.80
- 52 Week High
- HOPE $14.54
- TVTX $25.29
- Technical
- Relative Strength Index (RSI)
- HOPE 49.52
- TVTX 38.47
- Support Level
- HOPE $9.98
- TVTX $13.88
- Resistance Level
- HOPE $10.69
- TVTX $15.04
- Average True Range (ATR)
- HOPE 0.21
- TVTX 0.69
- MACD
- HOPE -0.02
- TVTX 0.02
- Stochastic Oscillator
- HOPE 39.77
- TVTX 24.43
About HOPE Hope Bancorp Inc.
Hope Bancorp Inc is a bank holding company engaged in providing financial services. It offers core business banking products for small and medium-sized businesses and individuals. Services offered by the bank include online banking, mobile banking, mortgage loans, credit cards, investment and wealth management services and other banking services.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.